United States Senator Bernie Sanders announced on Friday that leaders of Eli Lilly, Sanofi and Novo Nordisk will testify before the Senate Health Committee on May 10 to discuss lowering insulin prices.
The testimony comes after the three companies controlling the US market reduced the prices of most used insulin products by at least 70%. The decision came in response to the Biden administration's call to Congress to cap insulin prices at $35 per month, down from the previous $275.
Announcing the testimony of CEOs David Ricks, Paul Hudson and Lars Fruergaard Jorgensen, Senator Sanders stressed that "we must make certain, however, that those price reductions go into effect in a way that results in every American getting the insulin they need at an affordable price."
